Pemetrexed in Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Registration Number
- NCT01193959
- Lead Sponsor
- Armando Santoro, MD
- Brief Summary
Present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the ≥ second line setting in a large cohort of advanced non-small cell lung cancer (NSCLC) patients. The following biomarkers will be investigated with either immunohistochemistry, fluorescence in situ hybridization or genotyping: thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), aminoimidazole carboxamide ribonucleotide formyltransferase (ATIC/AICARFT), epidermal growth factor receptor (EGFR), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), v-myc myelocytomatosis viral oncogene homolog (MYC) and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
- Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor tissue available at our institution
- Patients treated with single agent pemetrexed for metastatic disease
- Availability of full clinical data
- Cytological diagnosis of advanced Non-small cell lung cancer
- Lack of tumor tissue at our institution
- Lack of full clinical data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association of each biomarker with treatment outcome in terms of response rate, time to progression, overall survival. one year
- Secondary Outcome Measures
Name Time Method Association of each biomarker with clinico-pathological features: histology, gender, age, smoking status, response to previous chemotherapy. one year
Trial Locations
- Locations (1)
Istituto Clinico Humanitas
🇮🇹Rozzano, Milano, Italy